Dr. Noah Biotech
Dr. Noah Biotech is a preclinical-stage South Korean biopharmaceutical company developing gene therapy pipelines for Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA), serving rare neuromuscular disease patients with high unmet medical need.
- Company typePrivate
- Founded2017
- HeadquartersSuwon, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
Dr. Noah Biotech firmographics
Firmographics- Name
- Dr. Noah Biotech
- Website
- https://drnoahbiotech.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Dr. Noah Biotech is a preclinical-stage South Korean biopharmaceutical company developing gene therapy pipelines for Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA), serving rare neuromuscular disease patients with high unmet medical need.
- Ownership category
- akta.pro rank
Dr. Noah Biotech industry classification
Industry- Product category
- Gene Therapy Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industries
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), AAV Vector Gene Therapy Developers (HLAAACAA)
Keywords
Where Dr. Noah Biotech is headquartered
LocationHeadquarters
- HQ city
- Suwon
- HQ country
- South Korea
- HQ region
- Asia
Markets served
Dr. Noah Biotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Dr. Noah Biotech product offering
Product offeringCore offering
Dr. Noah Biotech develops gene therapy drug candidates targeting two orphan disease indications: Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). The company is a preclinical-stage biopharmaceutical firm focused on leveraging gene therapy to address rare, severe neuromuscular disorders with high unmet medical need. Its deliverables are two proprietary drug pipelines (DMD Pipeline and SMA Pipeline) that are being advanced through preclinical R&D.
Differentiator
Problem solved
Functional benefit
Products and services
- DMD Pipeline
- SMA Pipeline
Quantifiable outcome
- Aiming to enter preclinical trials within one year of funding
Companies that use Dr. Noah Biotech
Customer profileSegments1 record
Ideal customer profiles2 records
Dr. Noah Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Dr. Noah Biotech partnerships and signals
Strategic signalScale indicators1 record
Dr. Noah Biotech competitors and assessment
Company assessmentMarket position
Customer concentration
Dr. Noah Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dr. Noah Biotech leadership team
Management profileNumber of profiles
Dr. Noah Biotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dr. Noah Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dr. Noah Biotech
What does Dr. Noah Biotech do?
Dr. Noah Biotech develops gene therapy drug candidates targeting two orphan disease indications: Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). The company is a preclinical-stage biopharmaceutical firm focused on leveraging gene therapy to address rare, severe neuromuscular disorders with high unmet medical need. Its deliverables are two proprietary drug pipelines (DMD Pipeline and SMA Pipeline) that are being advanced through preclinical R&D.
Is Dr. Noah Biotech a public or private company?
Dr. Noah Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Dr. Noah Biotech founded?
Dr. Noah Biotech was founded in 2017. It employs 11 to 50 people.
Where is Dr. Noah Biotech based?
Dr. Noah Biotech is headquartered in Suwon, South Korea, in the Asia region.
Does Dr. Noah Biotech have an API?
No public API is recorded for Dr. Noah Biotech.
What industry is Dr. Noah Biotech in?
Dr. Noah Biotech's product category is Gene Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2836.